On the stock market since 2001, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
No real growth (-3% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Sales run at $25.6M a year. A small number, but proof the product has real buyers.
It pays out $0.61 per share each year — regular cash for whoever holds the stock.
A loss of $23.8M against $25.6M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 60 sells against just 1 buy. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, BFZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BFZ is a high-risk stock — not yet profitable, and its future rides on its product catching on.